Cargando…

Extrapolation concept at work with biosimilar: a decade of experience in oncology

Detalles Bibliográficos
Autores principales:	Krendyukov, Andriy, Schiestl, Martin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5890855/ https://www.ncbi.nlm.nih.gov/pubmed/29644102 http://dx.doi.org/10.1136/esmoopen-2017-000319

Ejemplares similares

The ESMO position paper on biosimilars in oncology: enhancing the provision of accurate education and information
por: Schiestl, Martin, et al.
Publicado: (2017)

Epoetin Biosimilars in the Treatment of Renal Anemia: What Have We Learned from a Decade of European Experience?
por: Goldsmith, David, et al.
Publicado: (2018)

Extrapolation in Practice: Lessons from 10 Years with Biosimilar Filgrastim
por: Gascon, Pere, et al.
Publicado: (2019)

Epoetin Biosimilars in the Treatment of Chemotherapy-Induced Anemia: 10 Years’ Experience Gained
por: Aapro, Matti, et al.
Publicado: (2018)

Innovative oncology products: time to revisit the strategy development?
por: Krendyukov, Andriy
Publicado: (2019)

Clinical equivalence with G-CSF biosimilars: methodologic approach in a (neo)adjuvant setting in non-metastatic breast cancer
por: Krendyukov, A., et al.
Publicado: (2017)

Biosimilars and the extrapolation of indications for inflammatory conditions
por: Tesser, John RP, et al.
Publicado: (2017)

Biosimilar insulin concepts
por: Bloomgarden, Zachary T.
Publicado: (2022)

Biosimilars: Extrapolating the evidence. A roundtable discussion
por: Monk, Bradley J., et al.
Publicado: (2015)

HX575: established biosimilarity in the treatment of renal anemia and 10 years of clinical experience
por: Dellanna, Frank, et al.
Publicado: (2017)

Development and 10-year history of a biosimilar: the example of Binocrit(®)
por: Aapro, Matti, et al.
Publicado: (2018)

Biosimilar Drugs: What Would Be a Reasonable Extrapolation?
por: Gifoni, Markus A.C., et al.
Publicado: (2017)

Early Access Provision for Innovative Medicinal Products in Oncology: Challenges and Opportunities
por: Krendyukov, Andriy
Publicado: (2020)

Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices
por: Ebbers, Hans C., et al.
Publicado: (2016)

Evidence for some, extrapolation for others: Levonorgestrel IUDs and health equity in Gynecologic Oncology
por: Matthews, Benjamin J., et al.
Publicado: (2023)

Biosimilars in oncology
por: Tabernero, Josep
Publicado: (2018)

Biosimilars
por: Martin, Miguel
Publicado: (2018)

Treatment patterns and outcomes in patients with non‐small cell lung cancer receiving biosimilar filgrastim for prophylaxis of chemotherapy‐induced/febrile neutropaenia: Results from the MONITOR‐GCSF study
por: Aapro, Matti, et al.
Publicado: (2019)

Phase 3 LILAC study sets standard for clinical evaluation of oncology biosimilars
por: Kolberg, Hans-Christian, et al.
Publicado: (2019)

Ten years of biosimilars in Europe: development and evolution of the regulatory pathways
por: Schiestl, Martin, et al.
Publicado: (2017)

Risk management of biosimilars in oncology: each medicine is a work in progress
por: Vulto, Arnold G., et al.
Publicado: (2012)

Concepts and Challenges of Biosimilars in Breast Cancer: The Emergence of Trastuzumab Biosimilars
por: Uifălean, Alina, et al.
Publicado: (2018)

Early access provision: Awareness, educational needs and opportunities to improve oncology patients’ access to care
por: Krendyukov, Andriy, et al.
Publicado: (2022)

The arrival of biosimilar monoclonal antibodies in oncology: clinical studies for trastuzumab biosimilars
por: Barbier, Liese, et al.
Publicado: (2019)

Preparing for the incoming wave of biosimilars in oncology
por: Wolff-Holz, Elena, et al.
Publicado: (2018)

Clinical considerations for the development of biosimilars in oncology
por: Socinski, Mark A, et al.
Publicado: (2015)

The Path Towards a Tailored Clinical Biosimilar Development
por: Schiestl, Martin, et al.
Publicado: (2020)

Extrapolation and rational approximation: the works of the main contributors
por: Brezinski, Claude, et al.
Publicado: (2020)

Biosimilar and interchangeable: Inseparable scientific concepts?
por: de Mora, Fernando, et al.
Publicado: (2019)

The Development Pathway for Biosimilar Biotherapeutics
por: Zarbin, Marco
Publicado: (2020)

Here to Stay: Biosimilars in Hematology
por: Gribben, John, et al.
Publicado: (2019)

Nanoneuropharmacology: A challenging concept in pharmaceutical investigations for the next decade
por: Ramassamy, Charles, et al.
Publicado: (2011)

Interspecies extrapolation by physiologically based pharmacokinetic modeling
por: Ghallab, Ahmed
Publicado: (2015)

Correction: Preparing for the incoming wave of biosimilars in oncology
Publicado: (2018)

Barriers to Oncology Biosimilars Uptake in the United States
por: Nabhan, Chadi, et al.
Publicado: (2018)

The role of biosimilars in value-based oncology care
por: Patel, Kashyap B, et al.
Publicado: (2018)

Development of biosimilars in an era of oncologic drug shortages
por: Li, Edward, et al.
Publicado: (2015)

Regulatory considerations in oncologic biosimilar drug development
por: Macdonald, Judith C, et al.
Publicado: (2015)

Current and future roles of biosimilars in oncology practice
por: Konstantinidou, Sofia, et al.
Publicado: (2020)

Biosimilars in Oncology: Latest Trends and Regulatory Status
por: Joshi, Deeksha, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_5avdlp79h02vcuf71bh6mjriu6